安徽省某三级综合医院恶性肿瘤患者的分布及抗肿瘤药物的使用情况分析  

Distribution of Malignant Tumor Patients and Application of Anti-Tumor Drugs in a GradeⅢGeneral Hospital in Anhui

作　　者：李晓琦 庞一迪 庞晓青 LI Xiaoqi;PANG Yidi;PANG Xiaoqing(Research Center for Chinese Medicine Components and Microecology,Affiliated Hospital of Integrated Traditional Chinese and Western Medicine,Nanjing University of Chinese Medicine,Nanjing 210028,China;Research Center for Chinese Medicine Components and Microecology,Jiangsu Province Academy of Traditional Chinese Medicine,Nanjing 210028,China;School of Pharmaceutical Economics and Management,Anhui University of Chinese Medicine,Hefei 230000,China;Dept.of Pharmacy,People’s Hospital of Anhui Linquan County,Anhui Fuyang 236400,China)

机构地区：[1]南京中医药大学附属中西医结合医院中药组分与微生态研究中心,南京210028 [2]江苏省中医药研究院中药组分与微生态研究中心,南京210028 [3]安徽中医药大学医药经济管理学院,合肥230000 [4]安徽省临泉县人民医院药剂科,安徽阜阳236400

出　　处：《中国医院用药评价与分析》2025年第3期352-357,共6页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：国家自然科学基金资助项目(No.82204930);江苏省中医药科技发展计划青年人才项目(No.QN202110)。

摘　　要：目的:了解2023年安徽省某三级综合医院(以下简称“该院”)肿瘤住院患者的年龄和性别分布情况,以及门诊药房抗肿瘤药物的使用情况,为促进肿瘤疾病在县级医院的防治及抗肿瘤药物的合理使用提供依据。方法:调取2023年该院恶性肿瘤患者信息,对患者的年龄和性别分布情况进行统计分析;调取2023年该院门诊药房抗肿瘤药物的使用信息,对药品的销售数量、销售金额、限定日剂量(DDD)、用药频度(DDDs)、限定日费用(DDC)以及药品销售金额排序(B)/DDDs排序(A)等参数进行讨论分析。结果:2023年,该院患者数排序居前3位的恶性肿瘤分别为肺癌、肝癌和肠癌;上述3种恶性肿瘤患者中,男性患者数量均远高于女性患者;患者数量与年龄呈正相关,40岁之后患者数量急速增加;其中肺癌和肠癌患者的年龄大多在>70~80岁,而肝癌患者年龄相对较小,为>50~60岁。该院门诊药房抗肿瘤药物以小分子靶向药物为主,包含27种酪氨酸激酶抑制剂(TKI)。2023年,门诊药房销售数量最高的TKI为埃克替尼;销售金额排序居第1位的TKI为奥希替尼;DDDs排序居前3位的TKI为埃克替尼、安罗替尼和奥希替尼,其中埃克替尼的DDC为5.17元,B/A为3.00,表现出良好的同步性;奥希替尼和氟马替尼的B/A最低,仅为0.33,在27种TKI中同步性最差。结论:2023年该院门诊药房抗肿瘤药物使用情况总体合理,但仍需进一步加强监管力度,减轻患者负担,确保患者用药更加经济、安全。OBJECTIVE:To investigate the age and gender distribution of malignant tumor inpatients and application of anti-tumor drugs in outpatient pharmacy in a gradeⅢgeneral hospital(hereinafter referred to as“the hospital”)in Anhui in 2023,so as to provide references for promoting the prevention and treatment of tumor diseases in county-level hospitals and the rational application of anti-tumor drugs.METHODS:Information of malignant tumor patients in the hospital in 2023 was retrieved to analyze the age and gender distribution,application of anti-tumor drugs in the outpatient pharmacy of the hospital in 2023 was retrieved to analyze the parameters such as the consumption amount,consumption sum,defined daily dose(DDD),defined daily dose system(DDDs),defined daily cost(DDC)and sequence of drug consumption sum(B)/sequence of DDDs(A).RESULTS:In 2023,the top 3 malignant tumors ranked by the number of patients in the hospital were respectively lung cancer,liver cancer and intestinal cancer,the number of male patients was higher than that of female patients for all 3 malignant tumors mentioned above,the number of patients was positively correlated with age,and the number of patients increased rapidly after the age of 40 years,patients with lung cancer and intestinal cancer were mostly aged>70 to 80 years,while patients with liver cancer were relatively young,being in the range of>50 to 60 years.The anti-tumor drugs in outpatient pharmacy were mainly small-molecule targeted drugs,including 27 tyrosine kinase inhibitors(TKI).In 2023,the TKI with the largest consumption amount in the outpatient pharmacy was icotinib;the top 1 TKI ranked by consumption sum was osimertinib;the top 3 TKI ranked by DDDs were respectively icotinib,anlotinib and osimertinib,with icotinib having the DDC of 5.17 RMB and B/A of 3.00,which showed a good synchronization.Osimertinib and flumatinib had the lowest B/A of 0.33,with the worst synchronization among the 27 TKI.CONCLUSIONS:The application of anti-tumor drugs in outpatient pharmacy of the hospi

关 键 词：恶性肿瘤 年龄分布 抗肿瘤药物 销售金额 用药频度 限定日费用 排序比 

分 类 号：R979.1[医药卫生—药品]